Literature DB >> 11804704

Association of CSF apolipoprotein E, Abeta42 and cognition in Alzheimer's disease.

M Riemenschneider1, M Schmolke, N Lautenschlager, H Vanderstichele, E Vanmechelen, W G Guder, A Kurz.   

Abstract

A significant association between CSF Abeta42 and cognition in patients with Alzheimer's disease (AD) homozygous for the epsilon3 allele of the apolipoprotein E (apoE) has been described. In this study we extended our observations on apoE, as another plaque component, and investigated the association between CSF apoE concentrations and cognitive performance after stratification for the apoE genotype in 62 patients with AD, 19 other forms of dementia and 18 controls. CSF Abeta42 and apoE concentrations were significantly and positively associated with Mini Mental State Examination (MMSE) score in AD (Abeta42: r = 0.332; P = 0.026; apoE: r = 0.386; P = 0.006). For Abeta42 this association was exclusively present in epsilon3 homozygotes (r = 0.44; P = 0.014), whereas apoE was correlated with MMSE in epsilon4 hetero- or homozygotes subjects (epsilon4/epsilonX: r = 0.638; P = 0.004: epsilon4/epsilon4; r = 0.812; P = 0.05). No association was observed between CSF concentrations of Abeta42 and apoE. The significant relationship between MMSE and CSF Abeta42 in epsilon3 homozygotes and apoE in epsilon4 hetero- and homozygotes respectively may suggest that both proteins may be associated independently from each other with cognitive decline.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11804704     DOI: 10.1016/s0197-4580(01)00272-x

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  6 in total

1.  Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.

Authors:  Timo Grimmer; Matthias Riemenschneider; Hans Förstl; Gjermund Henriksen; William E Klunk; Chester A Mathis; Tohru Shiga; Hans-Jürgen Wester; Alexander Kurz; Alexander Drzezga
Journal:  Biol Psychiatry       Date:  2009-03-06       Impact factor: 13.382

Review 2.  CSF biomarkers for amyloid and tau pathology in Alzheimer's disease.

Authors:  Hanna Rosenmann
Journal:  J Mol Neurosci       Date:  2011-11-05       Impact factor: 3.444

Review 3.  [Visualization of amyloid with positron emission tomography. Useful improvement in the diagnosis of dementia?].

Authors:  T Grimmer; A Drzezga; A Kurz
Journal:  Nervenarzt       Date:  2010-05       Impact factor: 1.214

Review 4.  Neurochemical dementia diagnostics: assays in CSF and blood.

Authors:  Piotr Lewczuk; Joachim Hornegger; Rüdiger Zimmermann; Markus Otto; Jens Wiltfang; Johannes Kornhuber
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

Review 5.  The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES).

Authors:  C C Gispen-de Wied; M Kritsidima; A J A Elferink
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

6.  Apolipoprotein E Affects In Vitro Axonal Growth and Regeneration via the MAPK Signaling Pathway.

Authors:  Cheng Yin; Zong-Duo Guo; Zong-Ze He; Zhen-Yu Wang; Xiao-Chuan Sun
Journal:  Cell Transplant       Date:  2018-10-23       Impact factor: 4.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.